October 2018 Healthcare Deal Spending Breaks Even

Spending on healthcare deals in the month of October didn’t match the surge in deal volume (see separate post). At $9.4 billion, October 2018 posted a slight 4% gain over September, but was 25% lower than the $12.6 billion spent in October 2017. Of course, we can only go by disclosed prices, and several transactions […]

Chromosomes
Chromosomes

Biotechnology Gets the Usual January Boost

The Biotechnology sector roared to life in 2017, posting a record 209 transactions. That’s 20% higher than the 174 deals announced in 2016. The previous record for the sector was set in 2009, with 193 transactions announced in the space. Spending for those 209 deals in 2017 didn’t set new records, but did post an […]

Sanofi Rationalizes Its Vaccine Portfolio

Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including […]

MCOs Make Deals to Combat High Drug Costs

Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.

Big Pharma Pays Big for Biotech Pipelines

The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is […]

Pfizer Buys Medivation and More

Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in […]